Skip to main content

Table 2 Patients heterozygous for the MC4R Val103Ile polymorphism, grouped according to tumour type; presence or absence of cachexia is shown

From: Val103Ile polymorphism of the melanocortin-4 receptor gene (MC4R) in cancer cachexia

Type of cancer Heterozygotes for the 103Ile-allele cachectic I/II1,2 or related stages III/IV1,2 or related stages No data about stage n female n male
Lymphoma 9 0 5 4 0 3 6
Colorectal 7 0 1 6 0 2 5
Leukaemia 2 0 * * * 0 2
Other gastrointestinal 1 0 0 1 0 0 1
Lung 1 0 1 0 0 0 1
Breast 2 0 2 0 0 2 0
Leukaemia-early stages 2 100% * * * 1 1
Prostate 0 0 * * * 0 0
Others 1 (PNET5) 0 * * * 0 1
Total 25 8% * * * 8 17
  1. 1Lymphoma subgroups according to WHO (2001) and Ann Arbor classifications.
  2. +The 24 patients with CLL (classification of Binet) and the 44 patients with multiple myeloma (classification of Durie and Salmon) were excluded.
  3. 2UICC classification was used for colorectal and other gastrointestinal tumors, breast and lung cancer.
  4. 3The different classifications for leucaemia and the leukaemia-early stages could not be used for these groups.
  5. 4Patients with myelodysplastic syndromes (MDS) or myeloproliferative syndromes (MPD).
  6. 5PNET: Primitive Neuroectodermal Tumour
  7. *The classifications for these different tumour types could not be used for subgrouping.